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Abstract
Background: Barriers to HIV treatment among injection drug users (IDU) are a major public health concern.
However, there remain few long-term studies investigating key demographic and behavioral factors - and gender
differences in particular - that may pose barriers to antiretroviral therapy (ART), especially in settings with universal
healthcare. We evaluated access and adherence to ART in a long-term cohort of HIV-positive IDU in a setting
where medical care and antiretroviral therapy are provided free of charge through a universal healthcare system.
Methods: We evaluated baseline antiretroviral use and subsequent adherence to ART among a Canadian cohort of
HIV-positive IDU. We used generalized estimating equation logistic regression to evaluate factors associated with
95% adherence to antiretroviral therapy estimated based on prescription refill compliance.
Results: Between May 1996 and April 2008, 545 IDU participants were followed for a median of 23.8 months (Inter-
quartile range: 8.5 - 91.6), among whom 341 (63%) were male and 204 (37%) were female. Within the six-month
period prior to the baseline interview, 133 (39%) men and 62 (30%) women were on ART (p = 0.042). After
adjusting for clinical characteristics as well as drug use patterns measured longitudinally throughout follow-up,
female gender was independently associated with a lower likelihood of being 95% adherent to ART (Odds Ratio
[OR] = 0.70; 95% Confidence Interval: 0.53-0.93).
Conclusions: Despite universal access to free HIV treatment and medical care, female IDU were less likely to access
and adhere to antiretroviral therapy, a finding that was independent of drug use and clinical characteristics. These
data suggest that interventions to improve access to HIV treatment among IDU must be tailored to address unique
barriers to antiretroviral therapy faced by female IDU.
Background
During the past decade, there have been significant
advances in the treatment of HIV disease with the advent
of antiretroviral therapy (ART) [1]. ART has been shown
to suppress plasma HIV RNA, contributing to substantial
reductions in HIV-related morbidity and mortality
among people receiving treatment [2,3]. However, effec-
tive management of HIV disease requires high levels of
ART adherence [4,5], as incomplete adherence can detri-
mentally affect virological control and subsequently
disease progression, as well as contribute to elevated
rates of antiretroviral resistan c e[ 5 ] .T h e r e f o r e ,e n s u r i n g
that HIV-positive persons maintain high levels of ART
adherence is of critical clinical importance.
Although newer, simplified ART regimens have
enhanced treatment adherence [6], specific HIV-positive
populations, such as injection drug users (IDU), continue
to face barriers to accessing and adhering to ART. Recent
injection drug use is associated with both non-adherence
to ART and HIV disease progression [7,8], and many
I D Ul i v ei nu n s t a b l eh o u s i n g ,h a v eu n d i a g n o s e do r
untreated mental illness, high rates of incarceration,
and street-involved survival-lifestyles, which may all com-
plicate delivery of HIV-related treatments [9,10].
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variable that may explain barriers to effective HIV care.
However, although previous research has assessed factors
associated with access and adherence to ART among
IDU, there remains a paucity of research investigating
differences in adherence between male and female IDU
specifically, as most of the previous research has explored
adherence among either IDU generally or between non-
IDU men and women [11-15]. There remain few long-
term, prospective studies assessing gender as a factor that
affects adherence conducted within a setting of universal
healthcare.
British Columbia, Canada has a universally accessible,
publicly funded healthcare system without user fees or
other financial barriers to medical services, including all
HIV/AIDS care. This allows for investigation of HIV-
related outcomes without the potentially confounding
effect of financial barriers to medical care and HIV
treatment that may be present in other settings. There-
fore, we conducted the present study to investigate fac-
tors associated with adherence to ART among a
Canadian cohort of HIV-positive IDU and specifically
examined if gender differences in adherence to ART
existed in this context.
Methods
The AIDS Care Cohort to evaluate Exposure to Survival
Services (ACCESS) is a prospective observational cohort
of HIV-seropositive injection drug users (IDU) in Van-
couver, Canada. The cohort has been described in detail
previously [14,16,17], and was populated through snow-
ball sampling and extensive street outreach methods in
the city’s Downtown Eastside. Individuals were eligible
for ACCESS if they were aged 18 years or older, HIV
seropositive, had used injection drugs, and provided
written informed consent. At baseline and semi-
annually, participants answer a standardized interviewer-
administered questionnaire and provide blood samples
for serologic analysis.
As previously described [14,16,17], the local setting
is somewhat unique in that there is a universal health-
care system and a province-wide centralized antiretro-
viral dispensation program and HIV/AIDS laboratory
which enables a complete prospective profile of all
patient CD4 cell count determinations and plasma
HIV-1 RNA levels, as well as a complete prospective
profile of antiretroviral therapy use among cohort par-
ticipants. This includes the specific antiretroviral
agents and the prescribed dose, a validated measure of
patient adherence derived from prescription refill
compliance, which is described further below [17,18].
The study has been approved by the Providence
Health Care/University of British Columbia Research
Ethics Board. Plasma HIV-1 RNA was measured using
the Roche Amplicor Monitor assay (Roche Molecular
Systems, Mississauga, Canada).
In the present study, we included all participants who
w e r er e c r u i t e da n dc o m p l e t e da tl e a s to n ei n t e r v i e w
between May 1996 and April 2008, and excluded only
those where clinical data were unavailable. As indicated
above, the primary independent variable of interest was
gender and, to compare rates of ART use at baseline,
we evaluated access to ART at the time of recruitment
into the cohort by examining the proportion of partici-
pants who had been on ART in the 6-month period
prior to the baseline interview. Since we had long-term
prospective data, we then assessed the longitudinal pat-
tern of ART exposure by examining ART adherence
during the six-month period preceding each semi-
annual follow-up visit throughout follow-up. As in
previous studies using this validated and confidential
pharmacy dispensation data [17,18], we measured adher-
ence to therapy in each six-month period as a ratio of
the number of days ART was dispensed over the num-
ber of days an individual was eligible for ART and
defined adherence as equal to or greater than 95%
adherence to ART during this period.
We considered explanatory variables potentially asso-
ciated with the dependent variable including: gender
(female vs. male); age (<24 yrs vs. ≥24 yrs); ethnicity
(Aboriginal ancestry vs. other); daily injection heroin use
(yes vs. no); daily cocaine injection (yes vs. no); daily
crack cocaine smoking (yes vs. no); current methadone
use (yes vs. no); any treatment use (yes vs. no); educa-
tion (less than high school vs. other); employment (reg
job, temp work, self-emp vs. other); and unstable hous-
ing (yes vs. no). Age was defined as a dichotomous vari-
able according to the World Health Organization’s
definition of a ‘young person’, using the upper age limit
of 24 as the cut-off [19]. All dichotomous behavioural
variables referred to the six-month period prior to the
interview. As in our previous work [18], we defined
unstable housing as living in a single-room occupancy
hotel, shelter or being homeless. Clinical variables
included baseline HIV-1 RNA level (per log10copies/mL)
and CD4 cell count (per 100 cells/mm
3), using the clo-
sest measure within one year of the baseline.
W eb e g a nb yc o m p a r i n gt h er a t eo fA R Tu s ea tb a s e -
line. We then examined univariate associations between
the explanatory variables and ART adherence through-
out follow-up. Because serial measures for each variable
were available for each subject, we used generalised esti-
mating equations (GEE) for the analysis of correlated
data. This approach allows for the identification of fac-
tors associated with the outcome over the entire study
period. Data from every participant follow-up visit were
considered in this analysis. Missing data were addressed
through the GEE estimating mechanism which uses all
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from dropouts or intermittent missing. All non-missing
pairs of data are used in the estimators of the working
correlation parameters. Standard errors were calculated
using an exchangeable correlation structure, adjusted by
multiple observations for each individual. GEE models
have routinely been used to analyse datasets containing
repeated measures, including longitudinal IDU cohorts
[20,21].
Following examination of the univariate results we fit
a multivariate GEE logistic regression model using an a
priori defined model building protocol whereby we
included all explanatory variables with a univariate p-
value < 0.05. We also ran the models with interaction
terms for key independent variables in order to better
compare rates of adherence between men and women.
We conducted additional sub-analyses adjusting for key
clinical or demographic characteristics and for the year
of the baseline interview to account for advances in
antiretroviral therapy during the study period. All statis-
tical procedures were performed using SAS version 9.1
(SAS, Cary, NC, USA). All p-values are two-side.
Results
Between May 1996 and April 2008, 545 participants
were eligible for the present study, and there was a
median of 23.8 months (Inter-quartile range: 8.5 - 91.6)
of prospective follow-up. Of these study participants,
341 (63%) were male and 204 (37%) were female. The
characteristics of the study population stratified by gen-
der are shown in Table 1. As indicated in the table, 133
(39%) men and 62 (30%) women were on ART in the
six-month period prior to the baseline interview (p =
0.042). There were 1186 (26.6%) periods where indivi-
duals were adherent out of 4460 total observations.
Overall, 81 (19%) out of 422 males and 83 (29%) out of
287 females were excluded from the analysis as a result
of missing baseline CD4 count or viral load.
The results of the univariate GEE logistic regression
demonstrated that methadone use (Odds Ratio [OR] =
2.44 [95% CI: 2.01-2.96]; p < 0.001), and accessing any
addiction treatment (OR = 1.50 [95% CI: 1.26-1.79]; p <
0.001) were associated with being 95% adherent to ART,
whereas higher baseline viral load (OR = 0.54 [95% CI:
0.48-0.60]; p < 0.001), education (OR = 0.56 [95% CI:
0.37-0.85; p = 0.007] age less than 24 years (OR = 0.16
[95% CI: 0.08-0.31]; p < 0.001), daily heroin injection
(OR = 0.38 [95% CI: 0.30-0.48]; p < 0.001), daily cocaine
injection (OR = 0.48 [95% CI: 0.40-0.57]; p < 0.001), and
female gender (OR = 0.69 [95% CI: 0.52-0.90]; p =
0.006) were negatively associated with 95% adherence.
Table 2 outlines the results of the univariate GEE
analysis.
Multivariate GEE regression demonstrated that metha-
done use (OR = 2.35 [95% CI: 1.88-2.94]; p < 0.001) was
independently associated with 95% ART adherence.
Higher baseline viral load (OR = 0.81 [95% CI: 0.68-
0.97]; p = 0.018), age less than 24 years (OR = 0.27
[95% CI: 0.13-0.57]; p < 0.001), daily heroin injection
(OR = 0.56 [95% CI: 0.43-0.73]; p < 0.001), daily cocaine
injection (OR = 0.57 [95% CI: 0.47-0.71]; p < 0.001);
Table 1 Baseline socio-demographic, behavioural, and
clinical characteristics of ACCESS participants
†, stratified
by gender
Characteristic Male
n = 341
(63%)
Female
n = 204
(37%)
Odds Ratio
(95% CI)
p
value
Age
≥ 24 years 332 (97) 179 (88) 5.2 (2.4-11.3) <0.001
<24 years 9 (3) 25 (12)
Aboriginal
ethnicity
No 249 (73) 111 (54)
Yes 92 (27) 93 (46) 2.3 (1.6-3.3) <0.001
Daily heroin use*
No 264 (77) 129 (63)
Yes 77 (23) 75 (37) 2.0 (1.4-2.9) <0.001
Daily cocaine use*
No 227 (67) 126 (62)
Yes 114 (33) 78 (38) 1.2 (0.9-1.8) 0.256
Daily crack use*
No 271 (79) 142 (70) 1.7 (1.1-2.5) 0.009
Yes 70 (21) 62 (30)
Current
methadone use
No 251 (74) 125 (61)
Yes 90 (26) 79 (39) 1.8 (1.2-2.6) 0.003
Any treatment
No 140 (41) 75 (37)
Yes 201 (59) 129 (63) 1.2 (0.8-1.7) 0.320
Unstable housing
No 95 (28) 64 (31)
Yes 246 (72) 140 (69) 0.8 (0.6-1.2) 0.383
On ART at baseline
No 208 (61) 142 (70)
Yes 133 (39) 62 (30) 0.7 (0.5-1.0) 0.042
Viral load
(log10copies/mL)
≥ 100,000 66 (19) 32 (16) 1.3 (0.8-2.1) 0.281
<100,000 275 (81) 172 (84)
CD4+ count (cells/
mm
3)
≥ 200 261 (77) 164 (80) 0.8 (0.5-1.2) 0.294
<200 80 (23) 40 (20)
†Includes all eligible participants that completed at least one interview
between May 1996 and April 2008 and where baseline clinical data was
available. *Refers to the six-month period prior to the baseline interview.
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and, female gender (OR = 0.70 [95% CI: 0.53-0.93]; p =
0.013) were independently and negatively associated
with 95% adherence to ART. There were no statistical
interactions observed in the multivariate GEE analysis.
Table 3 and Figure 1 show results of the multivariate
GEE logistic regression.
We conducted several sub-analyses of behavioural and
clinical variables. A sub-analysis was conducted defining
drug use as a 6-level categorical variable using ‘daily inject-
ing’ as the reference level showed results that were consis-
tent with analyses defining drug use as a dichotomous
variable (data available from the corresponding author).
Sub-analyses adjusting for year of the baseline interview,
to account for advances in antiretroviral therapy during
the study period, were consistent with the primary analysis
(data available from the corresponding author). Addition-
ally, a sub-analysis of time-updated clinical variables to
determine if clinical outcomes affected adherence or drug
using behaviours demonstrated that, although cocaine use
was no longer significant, the gender effect remained
(OR = 0.56 [95% CI: 0.43-0.74]; p < 0.001).
Discussion
The present study demonstrates that female IDU are
approximately 30% less likely to adhere to ART, an
association that persisted after intensive covariate
adjustment. To our knowledge this is the first long-term
study to assess key demographic and behavioural factors
associated with ART adherence within a community-
recruited cohort and within a context of a universal
healthcare system, and implies that barriers to adher-
ence among female IDU that are not explained by finan-
cial barriers.
Although female gender remained significantly asso-
ciated with worse adherence in multivariate analyses, it
is noteworthy that the strength of the association dimin-
ished when we adjusted for drug using and other beha-
vioural variables. This implies that drug-using
characteristics, which may create barriers to ART adher-
ence, were more common among female IDU in our
setting and this was confirmed by our baseline gender
comparisons. These data suggest that women are more
engaged in street-involved, survival activities, and are
thereby more marginalized from the healthcare system,
which poses a barrier to ART access and adherence.
The importance of maintaining high levels of ART
adherence is well established [4,5], and ensuring that vul-
nerable and disadvantaged populations have equal access
to HIV treatment is crucial from both an individual and
Table 2 Univariate GEE*
j analysis of sociodemographic,
behavioural and clinical factors associated with ≥ 95%
ART adherence
Variable OR (95% CI) p-value
Gender
(Female vs. Male) 0.69 (0.52-0.90) 0.006
Age
(<24 yrs vs. ≥ 24 yrs) 0.16 (0.08-0.31) <0.001
Ethnicity
(Aboriginal vs. other) 0.97 (0.74-1.28) 0.841
Heroin use*
(Daily vs. not daily) 0.38 (0.30-0.48) <0.001
Cocaine use*
(Daily vs. not daily) 0.48 (0.40-0.57) <0.001
Crack use*
(Daily vs. not daily) 0.94 (0.78-1.13) 0.509
Methadone treatment
(Yes vs. no) 2.44 (2.01-2.96) <0.001
Other addiction treatment
†
(Yes vs. no) 1.50 (1.26-1.79) <0.001
Education
(less than highschool vs. other) 0.56 (0.37-0.85) 0.007
Employment
(reg job, temp work, self-emp vs. other) 1.11 (0.87-1.41) 0.401
Unstable housing
(Yes vs. no) 0.90 (0.76-1.07) 0.239
Viral load
(per log10copies/mL) 0.54 (0.48-0.60) <0.001
CD4+ count
(per 100 cells/mm
3) 0.95 (0.89-1.00) 0.047
*Refers to the previous six-month period.
†Defined as drug treatment other
than methadone in the past six months.
jGEE = Generalized Estimating
Equation.
Table 3 Multivariate GEE*
j analysis of sociodemographic,
behavioural and clinical factors associated with ≥ 95%
ART adherence
Variable OR (95% CI) p-value
Gender
(Female vs. Male) 0.70 (0.53-0.93) 0.013
Age
(<24 yrs vs. ≥ 24 yrs) 0.27 (0.13-0.57) <0.001
Heroin use*
(Daily vs. not daily) 0.56 (0.43-0.73) <0.001
Cocaine use*
(Daily vs. not daily) 0.57 (0.47-0.71) <0.001
Methadone treatment
(Yes vs. no) 2.35 (1.88-2.94) <0.001
Education
(less than highschool vs. other) 0.65 (0.43-0.98) 0.04
Viral load
(per log10copies/mL) 0.81 (0.68-0.97) 0.018
CD4+ count
(per 100 cells/mm
3) 0.89 (0.84-0.94) <0.001
*Refers to the previous six-month period.
†Defined as drug treatment other
than methadone in the past six months.
jGEE = Generalized Estimating
Equation.
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research from the COHERE cohort in Europe indicates
that IDU and women, and particularly female IDU, experi-
ence higher mortality rates even after achieving optimal
CD4 cell counts while on ART, underscoring the urgent
health needs of this population and the importance of
maintaining high rates of adherence [23]. However, there
are currently few long term studies pertaining to factors
associated with ART adherence among IDU, particularly
in settings where HIV care is provided free of charge. Pre-
vious research regarding ART adherence across multiple
populations in the U.S.A. found that, in a post-ART era,
socio-demographic and behavioural factors - such as lower
education status, lower income, lack of medical care cov-
erage, a history of frequent drug or alcohol use, African-
American race, and female gender - are more frequently
associated with access and adherence to ART than clinical
factors [12,24,25]. Importantly, female gender has been
shown to be associated with lower rates of ART adherence
across several sub-groups, including both IDU and non-
IDU [15,25,26]. Compounding this, a national U.S. study
found that female IDU were among the most disadvan-
taged sub-groups of vulnerable HIV-positive populations
and were about half as likely to receive ART compared to
homosexual males, even after adjusting for other socio-
demographic variables [27]. However, because these stu-
dies were conducted in the U.S., financial and other
barriers inherent to the American healthcare system make
it difficult to fully determine whether other factors may be
affecting the association with gender and other socio-
demographic characteristics. The present study enhances
the current body of research by demonstrating that gen-
dered barriers to ART adherence persist even in settings
with a universal healthcare system.
Research regarding methods to reduce barriers to
ART are limited, particularly concerning gendered bar-
riers, though the need for targeted interventions is clear
[23]. Some studies have suggested that health system
changes such as educating health care providers about
the disparities that exist among populations accessing
treatment, anonymous HIV testing and treatment sites,
and same-day clinic appointments or extended hours of
operation, may increase access and adherence to ART
among vulnerable, marginalized populations [24,27]. In
addition, providing women-only health and community-
based services, increasing efforts to improve self-efficacy
among women in engaging with the healthcare system,
as well as education dispelling misinformation and mis-
conception about HIV-treatment, may all contribute to
improving access and adherence among women and
female IDU, specifically [24,28]. However, as our ana-
lyses demonstrate, drug using characteristics and the
corollary of more survival-based activities, are also a sig-
nificant barrier to ART adherence among women and
are likely a first point for interventions that seek to
improve access to healthcare services among IDU
women.
There are some limitations to this study. Most impor-
tantly, as this is an observational study, the association
between gender and ART adherence should be inter-
preted with caution. It is possible that there are other
confounding factors that were not measured and
adjusted for in this study. However, our analysis
included a large number of explanatory variables and we
used a liberal ap r i o r idefined model fitting protocol
[18]. In addition, our measure of adherence was based
on prescription refill compliance, which measures some-
thing different than daily pill taking. With respect to
Figure 1 Factors independently associated with 95% ART adherence among HIV-positive injection drug users in GEE* logistic
regression. *GEE = Generalized Estimating Equation. Multivariate model fit.
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ence has been shown to predict virological suppression
[29], CD4 response [30], and mortality [17,18] and thus
the differences we observed are likely to be clinically sig-
nificant. Lastly, we do not feel that missing data played a
role in our results given that all non-missing pairs of
data are included as a result of using generalized esti-
mating equation logistic regression in the statistical ana-
lysis when employing generalized estimating equation
(GEE) logistic regression.
Conclusions
The current study demonstrates that female gender pre-
sents an additional barrier for access and adherence to
ART among injection drug users, independent of drug
use and other socio-behavioural and clinical characteris-
tics. This is evidence that even within a context where
medical care and ART are provided free to HIV-positive
individuals, there remain important healthcare access
differences between male and female IDU. Other socio-
structural factors are also critically important in affect-
ing equitable access to necessary HIV treatment [31],
and women often face barriers derived from their com-
paratively lower socio-economic status, and broader, sys-
temic inequities that persist even within a context of
universal healthcare. In order to improve access and
adherence to ART among IDU women, gender-specific
interventions should be developed which recognize
these unique barriers.
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